1
|
Wang Y, Nowicki MO, Wang X, Arnold WD, Fernandez SA, Mo X, Wechuk J, Krisky D, Goss J, Wolfe D, Popovich PG, Lawler S, Chiocca EA. Comparative effectiveness of antinociceptive gene therapies in animal models of diabetic neuropathic pain. Gene Ther 2013; 20:742-50. [PMID: 23235561 PMCID: PMC5771489 DOI: 10.1038/gt.2012.90] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Revised: 09/19/2012] [Accepted: 09/21/2012] [Indexed: 01/03/2023]
Abstract
Peripheral neuropathic pain is one of the most common and debilitating complications of diabetes. Several genes have been shown to be effective in reducing neuropathic pain in animal models of diabetes after transfer to the dorsal root ganglion using replication-defective herpes simplex virus (HSV)1-based vectors, yet there has never been a comparative analysis of their efficacy. We compared four different HSV1-based vectors engineered to produce one of two opioid receptor agonists (enkephalin or endomorphin), or one of two isoforms of glutamic acid decarboxylase (GAD65 or GAD67), alone and in combination, in the streptozotocin-induced diabetic rat and mouse models. Our results indicate that a single subcutaneous hindpaw inoculation of vectors expressing GAD65 or GAD67 reduced diabetes-induced mechanical allodynia to a degree that was greater than daily injections of gabapentin in rats. Diabetic mice that developed thermal hyperalgesia also responded to GAD65 or endomorphin gene delivery. The results suggest that either GAD65 or GAD67 vectors are the most effective in the treatment of diabetic pain. The vector combinations, GAD67+endomorphin, GAD67+enkephalin or endomorphin+enkephalin also produced a significant antinociceptive effect but the combination did not appear to be superior to single gene treatment. These findings provide further justification for the clinical development of antinociceptive gene therapies for the treatment of diabetic peripheral neuropathies.
Collapse
Affiliation(s)
- Y Wang
- Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Dardinger Laboratory for Neurooncology and Neurosciences, Columbus, OH, USA
| | - MO Nowicki
- Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Dardinger Laboratory for Neurooncology and Neurosciences, Columbus, OH, USA
| | - X Wang
- Department of Neuroscience and Center for Brain and Spinal Cord Repair, Columbus, OH, USA
| | - WD Arnold
- Division of Neuromuscular Medicine, Department of Neurology, Columbus, OH, USA
| | - SA Fernandez
- Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - X Mo
- Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH, USA
| | - J Wechuk
- Dyamid, Inc., PA, Pittsburgh, USA
| | - D Krisky
- Dyamid, Inc., PA, Pittsburgh, USA
| | - J Goss
- Dyamid, Inc., PA, Pittsburgh, USA
| | - D Wolfe
- Dyamid, Inc., PA, Pittsburgh, USA
| | - PG Popovich
- Department of Neuroscience and Center for Brain and Spinal Cord Repair, Columbus, OH, USA
| | - S Lawler
- Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Dardinger Laboratory for Neurooncology and Neurosciences, Columbus, OH, USA
| | - EA Chiocca
- Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Dardinger Laboratory for Neurooncology and Neurosciences, Columbus, OH, USA
| |
Collapse
|
2
|
Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M, Fink DJ, Glorioso JC. Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain 2007; 133:29-38. [PMID: 17395375 DOI: 10.1016/j.pain.2007.02.003] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2006] [Revised: 01/24/2007] [Accepted: 02/12/2007] [Indexed: 10/23/2022]
Abstract
Endomorphin-2 (EM-2) is a carboxy-amidated tetrapeptide that binds the mu-opioid receptor with high affinity and is analgesic in several animal models of pain. Endomorphin peptides have been isolated from bovine and human brain, but no DNA sequences corresponding to a potential preproendomorphin gene have been identified in human genome sequence databases. In this study we designed a tripartite synthetic gene to direct production, cleavage, and amidation of EM-2, and placed the endomorphin gene expression cassette in a replication defective Herpes simplex virus (HSV) vector (vEM2). Biosynthesis of amidated endomorphin-2 peptide was quantified by radioimmunoassay and the identity confirmed by mass spectroscopy following vEM2 transduction of cultured primary dorsal root ganglion neurons. Subcutaneous inoculation of vEM2 resulted in vector delivery to dorsal root ganglion where expression of EM-2 peptide from the engineered gene was confirmed by ELISA. vEM2 delivery provided an analgesic effect in the spinal nerve ligation model of neuropathic pain measured by reduction of mechanical allodynia and thermal hyperalgesia. The analgesic effect of vEM2 was blocked by intrathecal delivery of the mu-receptor antagonist CTOP. The gene construct design described represents a broadly useful platform for biosynthesis and delivery of carboxy-amidated peptides for therapeutic and experimental purposes, and the results demonstrate that HSV-gene transfer to sensory neurons provides an effective means to achieve local biosynthesis of endomorphin peptides for the treatment of chronic pain.
Collapse
Affiliation(s)
- Darren Wolfe
- Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, E1240 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261, USA
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Abstract
This paper is the 28th consecutive installment of the annual review of research concerning the endogenous opioid system, now spanning over a quarter-century of research. It summarizes papers published during 2005 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity, neurophysiology and transmitter release (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration and thermoregulation (Section 16); immunological responses (Section 17).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, NY 11367, USA.
| | | |
Collapse
|